These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 33230714)

  • 21. Maximum a posteriori bayesian estimation of mycophenolic acid pharmacokinetics in renal transplant recipients at different postgrafting periods.
    Prémaud A; Le Meur Y; Debord J; Szelag JC; Rousseau A; Hoizey G; Toupance O; Marquet P
    Ther Drug Monit; 2005 Jun; 27(3):354-61. PubMed ID: 15905807
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Limited Sampling Strategy to Estimate Exposure of Everolimus in Whole Blood and Peripheral Blood Mononuclear Cells in Renal Transplant Recipients Using Population Pharmacokinetic Modeling and Bayesian Estimators.
    Robertsen I; Debord J; Åsberg A; Marquet P; Woillard JB
    Clin Pharmacokinet; 2018 Nov; 57(11):1459-1469. PubMed ID: 29556934
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of Bayesian Forecasting Methods for Prediction of Tacrolimus Exposure Using Samples Taken on Two Occasions in Adult Kidney Transplant Recipients.
    Brooks E; Tett SE; Isbel NM; McWhinney B; Staatz CE
    Ther Drug Monit; 2021 Apr; 43(2):238-246. PubMed ID: 32932413
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of a population PK model of tacrolimus for adaptive dosage control in stable kidney transplant patients.
    Andreu F; Colom H; Grinyó JM; Torras J; Cruzado JM; Lloberas N
    Ther Drug Monit; 2015 Apr; 37(2):246-55. PubMed ID: 25254416
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effects of the CYP3A5*3 variant on tacrolimus pharmacokinetics and outcomes in Tunisian kidney transplant recipients.
    Charfi R; Bacha MM; Ben Fadhal M; Ferchichi K; El Jebari H; Gaies E; Klouz A; Abderrahim E; Ben Hamida F; Ben Abdallah T; Trabelsi S; Gorgi Y; Sfar I
    Tunis Med; 2023 Oct; 101(10):738-744. PubMed ID: 38465753
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Limited sampling strategy for estimating individual exposure of tacrolimus in pediatric kidney transplant patients.
    Zhao W; Fakhoury M; Baudouin V; Maisin A; Deschênes G; Jacqz-Aigrain E
    Ther Drug Monit; 2011 Dec; 33(6):681-7. PubMed ID: 22011724
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Population pharmacokinetics and bayesian estimator of cyclosporine in pediatric renal transplant patients.
    Irtan S; Saint-Marcoux F; Rousseau A; Zhang D; Leroy V; Marquet P; Jacqz-Aigrain E
    Ther Drug Monit; 2007 Feb; 29(1):96-102. PubMed ID: 17304156
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development and validation of limited sampling strategies for the estimation of mycophenolic acid area under the curve in adult kidney and liver transplant recipients receiving concomitant enteric-coated mycophenolate sodium and tacrolimus.
    Pawinski T; Luszczynska P; Durlik M; Majchrzak J; Baczkowska T; Chrzanowska M; Sobiak J; Glyda M; Kuriata-Kordek M; Kamińska D; Krajewska M; Klinger M
    Ther Drug Monit; 2013 Dec; 35(6):760-9. PubMed ID: 24192641
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic study of mycophenolate mofetil in patients with systemic lupus erythematosus and design of Bayesian estimator using limited sampling strategies.
    Zahr N; Amoura Z; Debord J; Hulot JS; Saint-Marcoux F; Marquet P; Piette JC; Lechat P
    Clin Pharmacokinet; 2008; 47(4):277-84. PubMed ID: 18336056
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development and evaluation of a simulation procedure to take into account various assays for the Bayesian dose adjustment of tacrolimus.
    Saint-Marcoux F; Debord J; Parant F; Labalette M; Kamar N; Rostaing L; Rousseau A; Marquet P
    Ther Drug Monit; 2011 Apr; 33(2):171-7. PubMed ID: 21383655
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Limited sampling strategies for estimation of tacrolimus exposure in kidney transplant recipients receiving extended-release tacrolimus preparation.
    El-Nahhas T; Popoola J; MacPhee I; Johnston A
    Clin Transl Sci; 2022 Jan; 15(1):70-78. PubMed ID: 34780122
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of tacrolimus exposure on extrarenal adverse effects in adult renal transplant recipients.
    Campagne O; Mager DE; Brazeau D; Venuto RC; Tornatore KM
    Br J Clin Pharmacol; 2019 Mar; 85(3):516-529. PubMed ID: 30414331
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ciclosporin population pharmacokinetics and Bayesian estimation in thoracic transplant recipients.
    Fruit D; Rousseau A; Amrein C; Rollé F; Kamar N; Sebbag L; Redonnet M; Epailly E; Marquet P; Prémaud A
    Clin Pharmacokinet; 2013 Apr; 52(4):277-88. PubMed ID: 23400901
    [TBL] [Abstract][Full Text] [Related]  

  • 34. AUC-guided dosing of tacrolimus prevents progressive systemic overexposure in renal transplant recipients.
    Scholten EM; Cremers SC; Schoemaker RC; Rowshani AT; van Kan EJ; den Hartigh J; Paul LC; de Fijter JW
    Kidney Int; 2005 Jun; 67(6):2440-7. PubMed ID: 15882290
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation.
    Niioka T; Satoh S; Kagaya H; Numakura K; Inoue T; Saito M; Narita S; Tsuchiya N; Habuchi T; Miura M
    Transplantation; 2012 Nov; 94(10):1013-9. PubMed ID: 23073468
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Population pharmacokinetics of ciclosporin in haematopoietic allogeneic stem cell transplantation with emphasis on limited sampling strategy.
    Wilhelm AJ; de Graaf P; Veldkamp AI; Janssen JJ; Huijgens PC; Swart EL
    Br J Clin Pharmacol; 2012 Apr; 73(4):553-63. PubMed ID: 21988410
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in paediatric liver transplant recipients.
    Kassir N; Labbé L; Delaloye JR; Mouksassi MS; Lapeyraque AL; Alvarez F; Lallier M; Beaunoyer M; Théorêt Y; Litalien C
    Br J Clin Pharmacol; 2014 Jun; 77(6):1051-63. PubMed ID: 24977292
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Limited sampling strategy using Bayesian estimation for estimating individual exposure of the once-daily prolonged-release formulation of tacrolimus in kidney transplant children.
    Zhao W; Maisin A; Baudouin V; Fakhoury M; Storme T; Deschênes G; Jacqz-Aigrain E
    Eur J Clin Pharmacol; 2013 May; 69(5):1181-5. PubMed ID: 23208323
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluating tacrolimus pharmacokinetic models in adult renal transplant recipients with different CYP3A5 genotypes.
    Hu C; Yin WJ; Li DY; Ding JJ; Zhou LY; Wang JL; Ma RR; Liu K; Zhou G; Zuo XC
    Eur J Clin Pharmacol; 2018 Nov; 74(11):1437-1447. PubMed ID: 30019212
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Limited Sampling Strategy for Estimation of Mycophenolic Acid Exposure in Adult Chinese Heart Transplant Recipients.
    Xiang H; Zhou H; Zhang J; Sun Y; Wang Y; Han Y; Cai J
    Front Pharmacol; 2021; 12():652333. PubMed ID: 33912061
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.